|
|
Blood, 15 February 2004, Vol. 103, No. 4, pp. 1454-1463.
Prepublished online as a Blood First Edition Paper on October 9, 2003; DOI 10.1182/blood-2003-06-2081.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
Nathalie Chevallier,
Connie M. Corcoran,
Christine Lennon,
Elizabeth Hyjek,
Amy Chadburn,
Vivian J. Bardwell,
Jonathan D. Licht, and
Ari Melnick
From the Department of Medicine, Mount Sinai School of Medicine, New York; the Department of Immunopathology, New York Presbyterian Hospital, New York; the Department of Developmental and Molecular Biology and Medical Oncology, Albert Einstein College of Medicine, Bronx, NY; and the Department of Genetics Cell Biology and Development/Cancer Center, University of Minnesota, Minneapolis.
The multiplicity of transcription factors involved in hematologic malignancies suggests a complicated scenario in which many different molecular mechanisms lead to malignant transformation. We hypothesized that some of these proteins might physically and functionally interact and thus mechanistically link different diseases. The ETO protein of t(8;21) acute myeloid leukemia (AML) is an excellent candidate as a common factor because it is normally expressed in human hematopoietic cells, it binds to histone deacetylases (HDACs), and it interacts with the PLZF protein of t(11;17) acute promyelocytic leukemia. To determine whether ETO functionally links a broader range of disease entities, we asked whether ETO forms a complex with the Bcl-6 oncoprotein of B-cell lymphomas. We found that ETO and Bcl-6 are coexpressed in normal and malignant lymphoid tissue, where they interact and colocalize in nuclear speckles. ETO binds to the fourth zinc finger of Bcl-6, enhances Bcl-6 repression of artificial and endogenous genes in an HDAC-dependent manner, and forms a complex with Bcl-6 on the promoters of its endogenous target genes in B-cell lymphoma cells. Therefore, ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematologic malignancies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Kumar, K. M. Cheney, R. McKirdy, P. M. Neilsen, R. B. Schulz, J. Lee, J. Cohen, G. W. Booker, and D. F. Callen
CBFA2T3-ZNF652 Corepressor Complex Regulates Transcription of the E-box Gene HEB
J. Biol. Chem.,
July 4, 2008;
283(27):
19026 - 19038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Mendez, J. M. Polo, J. J. Yu, M. Krupski, B. B. Ding, A. Melnick, and B. H. Ye
CtBP Is an Essential Corepressor for BCL6 Autoregulation
Mol. Cell. Biol.,
April 1, 2008;
28(7):
2175 - 2186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Moore, J. M. Amann, C. S. Williams, E. Tahinci, T. E. Farmer, J. A. Martinez, G. Yang, K. S. Luce, E. Lee, and S. W. Hiebert
Myeloid Translocation Gene Family Members Associate with T-Cell Factors (TCFs) and Influence TCF-Dependent Transcription
Mol. Cell. Biol.,
February 1, 2008;
28(3):
977 - 987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Parekh, J. M. Polo, R. Shaknovich, P. Juszczynski, P. Lev, S. M. Ranuncolo, Y. Yin, U. Klein, G. Cattoretti, R. D. Favera, et al.
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
Blood,
September 15, 2007;
110(6):
2067 - 2074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Gearhart, C. M. Corcoran, J. A. Wamstad, and V. J. Bardwell
Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets.
Mol. Cell. Biol.,
September 1, 2006;
26(18):
6880 - 6889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kumar, J. Manning, H. E. Spendlove, G. Kremmidiotis, R. McKirdy, J. Lee, D. N. Millband, K. M. Cheney, M. R. Stampfer, P. P. Dwivedi, et al.
ZNF652, A Novel Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription
Mol. Cancer Res.,
September 1, 2006;
4(9):
655 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Choi, K. E. Elagib, L. L. Delehanty, and A. N. Goldfarb
Erythroid Inhibition by the Leukemic Fusion AML1-ETO Is Associated with Impaired Acetylation of the Major Erythroid Transcription Factor GATA-1.
Cancer Res.,
March 15, 2006;
66(6):
2990 - 2996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Schuh, A. J. Tipping, A. J. Clark, I. Hamlett, B. Guyot, F. J. Iborra, P. Rodriguez, J. Strouboulis, T. Enver, P. Vyas, et al.
ETO-2 Associates with SCL in Erythroid Cells and Megakaryocytes and Provides Repressor Functions in Erythropoiesis
Mol. Cell. Biol.,
December 1, 2005;
25(23):
10235 - 10250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Miles, D. K. Crockett, M. S. Lim, and K. S. J. Elenitoba-Johnson
Analysis of BCL6-interacting Proteins by Tandem Mass Spectrometry
Mol. Cell. Proteomics,
December 1, 2005;
4(12):
1898 - 1909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Melnick, K. Adelson, and J. D. Licht
The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?
J. Clin. Oncol.,
June 10, 2005;
23(17):
3957 - 3970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu, T. Shen, L. Huynh, M. I. Klisovic, L. J. Rush, J. L. Ford, J. Yu, B. Becknell, Y. Li, C. Liu, et al.
Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia
Cancer Res.,
February 15, 2005;
65(4):
1277 - 1284.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
